DOZA offers programs with Ozempic (semaglutide), Retatrutide, Biopatid, and peptides — each product is selected individually. A specialist will evaluate your situation free of charge.

Ozempic (semaglutide 0.5–2 mg/week) delivers an average weight loss of 10–15% over 6 months. DOZA clients report sustained appetite reduction after just 1–2 injections.

Retatrutide is a triple GLP-1/GIP/glucagon agonist. In phase 2 clinical trials, participants achieved 24% weight loss over 48 weeks — the highest result among GLP-1 agonists studied at that time.

Message us on Telegram @Doza_sofia_bot — a specialist will evaluate your situation and select a product free of charge. Response within 5 minutes.